(Q45752095)

15 December 2017

title

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients (English)

1 reference

15 December 2017

author name string

S Kobold

1

1 reference

15 December 2017

J Isernhagen

2

1 reference

15 December 2017

K Hübel

3

1 reference

15 December 2017

N Kilic

4

1 reference

15 December 2017

C Bogner

5

1 reference

15 December 2017

N Frickhofen

6

1 reference

15 December 2017

C Bokemeyer

7

1 reference

15 December 2017

W Fiedler

8

1 reference

15 December 2017

language of work or name

English

0 references

publication date

22 November 2010

1 reference

15 December 2017

Bone Marrow Transplantation

published in

1 reference

15 December 2017

volume

46

1 reference

15 December 2017

issue

8

1 reference

15 December 2017

page(s)

1053-1056

1 reference

15 December 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2010.264

exact match

0 references

cites work

Management of poor-prognosis or relapsed germ-cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

High-dose chemotherapy in nonseminomatous germ cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

Effect of prior chemotherapy on hematopoietic stem cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2010.264

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BMT.2010.264

1 reference

15 December 2017

Dimensions Publication ID

1037751137

0 references

1 reference

15 December 2017